

Registration deadline 15 July 2024  
[rac@echa.europa.eu](mailto:rac@echa.europa.eu)

**Provisional Draft Agenda**  
**70th meeting of the Committee for Risk Assessment**  
**(RAC-70)**

**16-20 September 2024**

**Face-to-face/Hybrid meeting\***

**Monday, 16 September starts at 09.00**  
**Friday, 20 September ends at 13.15**

***Times are Helsinki times***

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

**RAC/A/70/2024**  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Action points from the previous meetings. Appointment of (co-)rapporteurs**

- 4.1 Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits

***For agreement***  
***Closed session –***  
***No remote connection***

---

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely

## **Item 5 – Work plan and General RAC procedures**

5.1 Report on RAC related activities and RAC Work Plan for all processes

***For information***

5.2 Update of RAC accredited stakeholders' list (closed session)

***For discussion and agreement***

***Doc to be distributed***

***Restricted***

***Closed session –***

***No remote connection***

5.3 Selection of RAC co-opted members (closed session)

***For discussion and agreement***

***Doc to be distributed***

***Restricted***

***Closed session –***

***No remote connection***

## **Item 6 – Requests under Article 77(3)(c)**

None.

***For adoption***

## **Item 7 – Health based exposure limits at the workplace**

### **7.1 General OEL issues**

1. OEL regulatory framework presentation by DG EMPL

### **7.2 Opinions for discussion**

1. 4,4-Isopropylidenediphenol (Bisphenol A)
2. Silicon carbide fibres
3. Pyrocatechol

***For discussion***

## **Item 8 – Harmonised classification and labelling (CLH)**

### **8.1 General CHL issues**

1. Report from the July CLH Working Group

***For information***

***Doc to be distributed***

### **8.2 CLH dossiers**

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely

## 1. Hazard classes for agreement without plenary debate (A-list)

- **3,5-Dimethylpyrazole:** acute oral toxicity, STOT RE, adverse effects on or via lactation
- **3,4-Dimethyl-1H-pyrazole:** acute toxicity via all routes, STOT RE, adverse effects on or via lactation
- **3,4-Dimethyl-1H-pyrazol-1-ium dihydrogen phosphate:** acute toxicity via all routes, STOT RE, adverse effects on or via lactation
- **Borate minerals group:** adverse effects on or via lactation
- **Thermally treated garlic juice:** physical hazards, acute toxicity via all routes, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, respiratory sensitisation, STOT SE, STOT RE, mutagenicity, carcinogenicity, reproductive toxicity, aspiration hazard, hazards to the aquatic environment, hazards to the Ozone layer
- **Fluazaindolizine (ISO):** physical hazards, hazards to the aquatic environment
- **[Ethane-1,2-diylbis[nitrilobis(methylene)]]tetrakisphosphonic acid:** mutagenicity, STOT RE
- **[Ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, calcium sodium salt:** mutagenicity, STOT RE
- **[Ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, potassium salt:** mutagenicity, STOT RE
- **[Ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, sodium salt:** mutagenicity, STOT RE
- **2-Pyrrolidone:** reproductive toxicity – fertility and effects on or via lactation
- **Rape oil; rape seed oil:** physical hazards, acute toxicity via all routes, skin corrosion/irritation, serious eye damage/eye irritation, respiratory sensitisation, skin sensitisation, STOT SE, STOT RE, mutagenicity, carcinogenicity, reproductive toxicity, aspiration hazard, hazards to the aquatic environment
- **Tebuconazole (ISO):** acute toxicity via all routes, skin corrosion/irritation, serious eye damage/eye irritation, respiratory sensitisation, skin sensitisation, STOT SE, STOT RE, mutagenicity, carcinogenicity, effects on or via lactation, aspiration hazard
- **Eugenol (dossier from the Spanish Competent Authority):** physical hazards, acute toxicity via all routes, skin corrosion/irritation, serious eye damage/eye irritation, mutagenicity, carcinogenicity, STOT SE, STOT RE, reproductive toxicity, hazard to the aquatic environment, hazard to the Ozone layer
- **Eugenol (dossier from the Danish Competent Authority and includes only Skin Sensitisation):** skin sensitisation
- **Silver nitrate:** physical hazards, hazards to the aquatic environment

## 2. Hazard classes for agreement with plenary debate

- 8.2.1 **3,5-Dimethylpyrazole** (EC 200-657-5, CAS 67-51-6): reproductive toxicity – fertility and development
- 8.2.2 **3,4-Dimethyl-1H-pyrazole** (EC 429-130-1, CAS 2820-37-3): reproductive toxicity – fertility and development

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely

- 8.2.3 **3,4-Dimethyl-1H-pyrazol-1-ium dihydrogen phosphate** (EC 424-640-9, CAS 202842-98-6): *reproductive toxicity – fertility and development*
- 8.2.4 **Borate minerals group: reproductive toxicity – fertility and development**
- 8.2.4.1 Ulexite ( $\text{CaNaH}_{12}(\text{BO}_3)_5 \times 2\text{H}_2\text{O}$ ) [1] ulexite ( $\text{CaNaH}_{12}(\text{BO}_3)_5 \times 2\text{H}_2\text{O}$ ), calcined [2] (EC - [1] 296-662-5 [2], CAS 1319-33-1 [1] 92908-33-3 [2])
- 8.2.4.2 Colemanite ( $\text{CaH}(\text{BO}_2)_3 \times 2\text{H}_2\text{O}$ ) [1] boron calcium oxide ( $\text{B}_6\text{Ca}_2\text{O}_{11}$ ), hydrate (1:5) [2] colemanite, calcined [3] (EC - [1] - [2] 296-640-5 [3], CAS 1318-33-8 [1] 854267-07-5 [2] 92908-12-8 [3])
- 8.2.4.3 Tincalconite ( $\text{B}_4\text{Na}_2\text{O}_7 \times 5\text{H}_2\text{O}$ ) (EC -, CAS 12045-88-4)
- 8.2.5 **Fluazaindolizine (ISO); 8-chloro-N-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide** (EC -, CAS 1254304-22-7): *all relevant human health hazard classes*
- 8.2.6 **[Ethane-1,2-diylbis[nitrilobis(methylene)]]tetrakisphosphonic acid** (EC 215-851-5, CAS 1429-50-1): *carcinogenicity*
- 8.2.7 **[Ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, calcium sodium salt** (EC 287-370-9, CAS 85480-89-3): *carcinogenicity*
- 8.2.8 **[Ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, potassium salt** (EC 251-910-1, CAS 234274-30-1): *carcinogenicity*
- 8.2.9 **[Ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, sodium salt** (EC 244-742-5, CAS 22036-77-7): *carcinogenicity*
- 8.2.10 **2-Pyrrolidone; pyrrolidin-2-one** (EC 210-483-1, CAS 616-45-5): *reproductive toxicity – development*
- 8.2.11 **Tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol** (EC 403-640-2; CAS 107534-96-3): *reproductive toxicity – fertility and development*
- 8.2.12 **Talc** ( $\text{Mg}_3\text{H}_2(\text{SiO}_3)_4$ ) (EC 238-877-9; CAS 14807-96-6):
- 8.2.13 Burgeonal group: all relevant hazard classes**
- 8.2.13.1 2-(4-*tert*-butylbenzyl) propionaldehyde (EC 201-289-8, CAS 80-54-6)
- 8.2.13.2 4-*tert*-butylbenzoic acid (EC 202-696-3, CAS 98-73-7)
- 8.2.13.3 3-(4-*tert*-butylphenyl)propionaldehyde [1] 4-*tert*-butyltoluene [2] 4-*tert*-butylbenzaldehyde [3] methyl 4-*tert*-butylbenzoate [4] (EC 242-016-2 [1] 202-675-9 [2] 213-367-9 [3] 247-768-5 [4], CAS 18127-01-0 [1] 98-51-1 [2] 939-97-9 [3] 26537-19-9 [4])
- 8.2.14 Cyclamal group: all relevant hazard classes**
- 8.2.14.1 *p*-cymene; 1-isopropyl-4-methylbenzene and 3-*p*-cumenyl-2-methylpropionaldehyde (EC 202-796-7, CAS 99-87-6) and
- 8.2.14.2 2-methyl-3-(4-isopropylphenyl)propanal [1]; 3-(*p*-cumenyl)propionaldehyde; 3-(4-isopropylphenyl)propanal [2] ; 4-isopropylbenzaldehyde; cuminic aldehyde [3] ; 4-isopropylbenzoic acid; cuminic acid [4] (EC 203-161-7 [1]; 231-885-3 [2]; 204-516-9 [3]; 208-642-5 [4], CAS 103-95-7 [1]; 7775-00-0 [2]; 122-03-2 [3]; 536-66-3 [4])
- 8.2.15 Silver nitrate** (EC 231-853-9, CAS 7761-88-8): *part of HH hazard classes*

***For discussion and adoption***

## **Item 9 – Restrictions**

### **9.1 General restriction issues**

- Report from the September REST Working Group

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely

## **9.2 Restriction Annex XV dossiers**

- a) Opinion development on Universal per- and polyfluoroalkyl substances (UPFAS) restriction proposal -state of play and next steps

**For information**

- b) Evaluation of sector-/use-specific aspects of UPFAS restriction proposal:

- i. Waste emissions (cont.)
- ii. Textiles, upholstery, leather, apparel, carpets (TULAC)
- iii. Food contact materials and packaging
- iv. Petroleum and mining

**For discussion**

## **Item 10 – Authorisation**

### **10.1 General authorisation issues**

1. Update on incoming/future applications and horizontal issues

**For information/discussion**

### **10.2 Authorisation applications**

#### **1. Discussion on key issues**

1. 364\_CT\_CTACSub2 (12 uses)

**For discussion**

### **10.3 Agreement on draft opinions**

#### **1. Draft opinions for agreement without plenary debate (A-list)**

To be announced at a later stage.

**For agreement**

#### **2. Draft opinions for agreement with plenary debate**

1. 352\_DEHP\_Baxter (3 uses)
2. 354\_RR1\_CT\_Airbus (2 uses)
3. 355\_RR1\_SD\_Airbus (1 use)
4. 356\_RR1\_SD\_AD-International (1 use)
5. 357\_RR1\_PD\_Lynred (1 use)
6. 358\_RR1\_AsA\_Circuit (1 use)
7. 359\_RR1\_CT\_Circuit (1 use)
8. 361\_TEL\_Trafigura (1 use)
9. 362\_TEL\_Warter-Fuels (1 use)

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely

***For discussion and agreement***

#### **10.4 Adoption of opinions**

To be announced at a later stage.

***For discussion and adoption***

##### **Item 11 – Drinking Water Directive**

1. Update on Drinking Water Directive (DWD)

***For information***

##### **Item 12 – AOB**

##### **Item 13 – Minutes of RAC-70**

1. Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-70

***For adoption***

PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-70  
Please note that timings are approximate. Changes may be made by the Chair before and during the meeting in order to accommodate the discussions.

***Times are Helsinki times***

**Monday 16 September 2024: Morning session**

09:00	09:20	ADMIN	Welcome and apologies
09:20	09:25	ADMIN	Adoption of the agenda
09:25	09:30	ADMIN	Declarations of conflicts of interest to the Agenda
09:30	09:40	ADMIN	Report on RAC-69 action points, written procedures and update on other ECHA bodies
09:40	10:30	AFA	11 ADCR RRs, 10 ADCR AfAs, 346_CT_Safran_landing_systems, 347_CT_Safran_Aircraft_Engines - adoption of opinions
10:30	11:00		<i>Coffee break</i>
11:00	12:30	OEL	4,4-Isopropylidenediphenol (Bisphenol A) - opinion adoption
12:30	13:30		<i>Lunch</i>

**Monday 16 September 2024: Afternoon session**

13:30	14:30	OEL	4,4-Isopropylidenediphenol (Bisphenol A) <b>contd.</b>
14:30	15:30	OEL	Silicon carbide fibres - first discussion
15:30	16:00		<i>Coffee break</i>
16:00	16:30	OEL	Silicon carbide fibres <b>contd.</b>
16:30	18:00	OEL	Pyrocatechol - first discussion
18:00	18:15	OEL	OEL regulatory framework by DG EMPL

**Tuesday 17 September 2024: Morning session**

09:00	10:00	RESTR	General Restrictions issues: - Report from the September REST Working Group - Review of the Conformity Check procedure
10:00	10:05	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): UPFAS restriction proposal: State of play and next steps
10:05	11:05	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): Draft opinion with focus on Waste emissions ( <i>cont.</i> )
11:05	11:35		<i>Coffee break</i>
11:35	13:00	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): Textiles, upholstery, leather, apparel, carpets (TULAC)
13:00	14:00		<i>Lunch</i>

**Tuesday 17 September 2024: Afternoon session**

14:00	14:35	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): Textiles, upholstery, leather, apparel, carpets (TULAC) <b>(cont.)</b>
14:35	16:00	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): Food contact materials and packaging
16:00	16:30		<i>Coffee break</i>

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely

16:30	17:05	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): Food contact materials and packaging ( <b>cont.</b> )
17:05	18:35	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): Petroleum and mining

***Dinner - Restaurant Kulta***

**Wednesday 18 September 2024: Morning session**

09:00	09:10	CLH	Report from the July CLH Working Group
09:10	09:30	CLH	Hazard classes for agreement without plenary debate (A-list): - Based on RAC members' comments - Based on the RAC WG CLH outcome
09:30	11:00	CLH	Talc ( $Mg_3H_2(SiO_3)_4$ )
11:00	11:30		<i>Coffee break</i>
11:30	12:00	CLH	Tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol
12:00	12:30	CLH	2-pyrrolidone; pyrrolidin-2-one
12:30	13:30		<i>Lunch</i>

**Wednesday 18 September 2024: Afternoon session**

13:30	14:30	CLH	3,5-dimethylpyrazole; 3,4-dimethyl-1 <i>H</i> -pyrazole; 3,4-dimethyl-1 <i>H</i> -pyrazol-1-ium dihydrogen phosphate
14:30	15:30	CLH	Silver nitrate
15:30	16:00		<i>Coffee break</i>
16:00	17:30	CLH	Fluazaindolizine (ISO); 8-chloro- <i>N</i> -[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)imidazo[1,2- <i>a</i> ]pyridine-2-carboxamide

**Thursday 19 September 2024: Morning session**

09:00	09:15	AFA	AFA general issue: - Update on incoming/future applications and horizontal issues
09:15	09:40	AFA	A-list agreement on AFAs
09:40	11:00	AFA	AFA segment I
11:00	11:30		<i>Coffee break</i>
11:30	13:00	AFA	AFA segment II
13:00	14:00		<i>Lunch</i>

**Thursday 19 September 2024: Afternoon session**

14:00	14:15	ADMIN	Update of RAC stakeholders list <b>Closed session</b>
14:15	14:20	ADMIN	Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits <b>Closed session</b>
14:20	15:00	ADMIN	Selection of RAC co-opted members <b>Closed session</b>
15:00	16:00	AFA	AFA segment III
16:00	16:30		<i>Coffee break</i>

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely



16:30 18:30 AFA AFA segment IV

**Friday 20 September 2024: Morning session**

09:00	09:30	DWD	Update on Drinking Water Directive (DWD)
09:30	11:30	CLH	Burgeonal group: 2-(4- <i>tert</i> -butylbenzyl) propionaldehyde; 4- <i>tert</i> -butylbenzoic acid; 3-(4- <i>tert</i> -butylphenyl)propionaldehyde [1] 4- <i>tert</i> - butyltoluene [2] 4- <i>tert</i> -butylbenzaldehyde [3] methyl 4- <i>tert</i> -butylbenzoate [4] Cyclamal group: <i>p</i> -cymene; 1-isopropyl-4-methylbenzene and 3- <i>p</i> -cumenyl- 2-methylpropionaldehyde and 2-methyl-3-(4-isopropylphenyl)propanal [1]; 3-( <i>p</i> - cumenyl)propionaldehyde; 3-(4-isopropylphenyl)propanal [2] ; 4-isopropylbenzaldehyde; cuminic aldehyde [3] ; 4- isopropylbenzoic acid; cuminic acid [4]
11:30	12:00		<i>Coffee break</i>
12:00	12:30	CLH	Borate minerals group: ulexite ( $\text{CaNaH}_{12}(\text{BO}_3)_5 \times 2\text{H}_2\text{O}$ ) [1] ulexite ( $\text{CaNaH}_{12}(\text{BO}_3)_5$ $\times 2\text{H}_2\text{O}$ ), calcined [2] colemanite ( $\text{CaH}(\text{BO}_2)_3 \times 2\text{H}_2\text{O}$ ) [1] boron calcium oxide ( $\text{B}_6\text{Ca}_2\text{O}_{11}$ ), hydrate (1:5) [2] colemanite, calcined [3] tinalconite ( $\text{B}_4\text{Na}_2\text{O}_7 \times 5\text{H}_2\text{O}$ )
12:30	13:00	CLH	[ethane-1,2- diylbis[nitrilobis(methylene)]]tetrakisphosphonic acid; [ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, calcium sodium salt; [ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, potassium salt; [ethylenebis[nitrilobis(methylene)]]tetrakisphosphonic acid, sodium salt
13:00	13:15	ADMIN	Adoption of the RAC-70 report and closure of the meeting

***END OF THE PLENARY***

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely